Johnson & Johnson says CareFirst lacks standing to challenge enforceability of Stelara patent in US antitrust case
MLex Summary: CareFirst, as an indirect purchaser of Stelara, cannot collaterally attack the enforceability of a Johnson & Johnson patent covering a method for using ustekinumab, J&J told a US federal...To view the full article, register now.
Already a subscriber? Click here to view full article